Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

This double-blind placebo-controlled study (n=34) explored the effects of microdosing psilocybin (0.5g of dried mushrooms) on subjective experience, behaviour, creativity, perception, cognition, and brain activity. In participants who correctly identified their experimental condition, the acute effects were more intense for the active dose compared to placebo and these effects were accompanied by reduced EEG in the theta band. However, in another blow to microdosing, no evidence was found to support enhanced well-being, creativity and cognitive function. It is likely that expectation underlies the positive effects of microdosing.

Abstract

“The use of low sub-perceptual doses of psychedelics (“microdosing”) has gained popularity in recent years. Although anecdotal reports claim multiple benefits associated with this practice, the lack of placebo-controlled studies severely limits our knowledge of microdosing and its effects. Moreover, research conducted in standard laboratory settings could fail to capture the motivation of individuals engaged or planning to engage in microdosing protocols, thus underestimating the likelihood of positive effects on creativity and cognitive function. We recruited 34 individuals starting to microdose with psilocybin mushrooms (Psilocybe cubensis), one of the materials most frequently used for this purpose. Following a double-blind placebo-controlled experimental design, we investigated the acute and short-term effects of 0.5 g of dried mushrooms on subjective experience, behavior, creativity (divergent and convergent thinking), perception, cognition, and brain activity. The reported acute effects were significantly more intense for the active dose compared to the placebo, but only for participants who correctly identified their experimental condition. These changes were accompanied by reduced EEG power in the theta band, together with preserved levels of Lempel-Ziv broadband signal complexity. For all other measurements there was no effect of microdosing except for few small changes towards cognitive impairment. According to our findings, low doses of psilocybin mushrooms can result in noticeable subjective effects and altered EEG rhythms, but without evidence to support enhanced well-being, creativity and cognitive function. We conclude that expectation underlies at least some of the anecdotal benefits attributed to microdosing with psilocybin mushrooms.”

Authors: Federico Cavanna, Stephanie Muller, Laura A. de la Fuente, Frederico Zamberlan, Matias Palmucci, Lucie Janeckova, Martin Kuchar, Carla Pallavicini & Enzo Tagliazucchi

Become a psychedelic insider!

With a free Blossom membership you will always be in the know.

📰 Weekly newsletter about the psychedelic research

✔️ Unlimited access to our database and original articles

🖊️ Add (private) notes and comments to each page

Make an account

Find this paper

Microdosing with psilocybin mushrooms: a double-blind placebo-controlled study

https://doi.org/10.1038/s41398-022-02039-0

Open Access | Google Scholar | Backup | 🕊

Published in
Translational Psychiatry
August 2, 2022
0 citations

Study details

Compounds studied
Psilocybin

Topics studied
Microdosing

Study characteristics
Placebo-Controlled Double-Blind

Participants
34 Humans

Authors

Authors associated with this publication with profiles on Blossom

Enzo Tagliazucchi
Enzo Tagliazucchi is the head of the Consciousness, Culture and Complexity Group at the Buenos Aires University, a Professor of Neuroscience at the Favaloro University, and a Marie Curie fellow at the Brain and Spine Institute in Paris. His main interest is the study of human consciousness as embedded within society and culture.

Institutes

Institutes associated with this publication

University of Buenos Aires
UBA is home to the Consciousness, Culture and Complexity & Phalaris Labs. Both labs are led by Enzo Tagliazucchi

0 Comments
Inline Feedbacks
View all comments